(Q36620561)

15 August 2017

High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma (English)

1 reference

15 August 2017

1 reference

Halme M

1

1 reference

15 August 2017

Knuuttila A

2

1 reference

15 August 2017

Vehmas T

3

1 reference

15 August 2017

Tammilehto L

4

1 reference

15 August 2017

Mäntylä M

5

1 reference

15 August 2017

Salo J

6

1 reference

15 August 2017

Mattson K

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

80

1 reference

15 August 2017

11

1 reference

15 August 2017

1781-1785

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690597

15 August 2017

0 references

cites work

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

Chemotherapy in malignant pleural mesothelioma. A review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

A review of chemotherapy trials for malignant mesothelioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesothelioma cell lines

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363122

Effects of natural interferon alpha, natural tumor necrosis factor alpha and their combination on human mesothelioma xenografts in nude mice

28 June 2018

1 reference

12 December 2020

Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study

1 reference

12 December 2020

Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma

1 reference

12 December 2020

High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases

1 reference

12 December 2020

A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction

1 reference

12 December 2020

High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.

1 reference

12 December 2020

Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice

1 reference

12 December 2020

Effect of interferon-alpha 2a on malignant mesothelioma

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6690597

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

10468296

1 reference